Analysts Set Enanta Pharmaceuticals Inc (ENTA) Price Target at $108.25

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has been given a consensus recommendation of “Hold” by the ten brokerages that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $108.25.

A number of research analysts have issued reports on ENTA shares. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $126.00 price objective on the stock in a research report on Wednesday, July 25th. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th. JMP Securities reissued a “buy” rating and set a $120.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, July 31st. UBS Group downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 8th. Finally, Oppenheimer set a $100.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, August 14th.

Enanta Pharmaceuticals stock traded down $0.85 during mid-day trading on Monday, reaching $79.03. 256,900 shares of the company traded hands, compared to its average volume of 240,240. The company has a market cap of $1.55 billion, a P/E ratio of 86.85 and a beta of 1.04. Enanta Pharmaceuticals has a 52-week low of $44.52 and a 52-week high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.98 by ($0.01). The company had revenue of $57.26 million for the quarter, compared to analysts’ expectations of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post 3.56 EPS for the current fiscal year.

In other news, VP Nathalie Adda sold 4,155 shares of the business’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $92.32, for a total transaction of $383,589.60. Following the sale, the vice president now owns 4,465 shares in the company, valued at approximately $412,208.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Tim Ocain sold 25,000 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $83.64, for a total transaction of $2,091,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,310 shares of company stock worth $2,870,644. Company insiders own 10.56% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 2.9% during the 2nd quarter. BlackRock Inc. now owns 2,433,000 shares of the biotechnology company’s stock valued at $281,985,000 after buying an additional 68,564 shares in the last quarter. Rhumbline Advisers boosted its stake in Enanta Pharmaceuticals by 1.9% in the 2nd quarter. Rhumbline Advisers now owns 37,550 shares of the biotechnology company’s stock worth $4,352,000 after purchasing an additional 691 shares in the last quarter. ClariVest Asset Management LLC boosted its stake in Enanta Pharmaceuticals by 98.7% in the 2nd quarter. ClariVest Asset Management LLC now owns 21,661 shares of the biotechnology company’s stock worth $2,510,000 after purchasing an additional 10,761 shares in the last quarter. Zeke Capital Advisors LLC bought a new position in Enanta Pharmaceuticals in the 2nd quarter worth about $216,000. Finally, Acadian Asset Management LLC boosted its stake in Enanta Pharmaceuticals by 72.4% in the 2nd quarter. Acadian Asset Management LLC now owns 381,729 shares of the biotechnology company’s stock worth $44,242,000 after purchasing an additional 160,344 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply